SAGE THERAPEUTICS INC. news, videos and press releases - Page 6
For more news please use our advanced search feature.
SAGE THERAPEUTICS INC. - More news...
SAGE THERAPEUTICS INC. - More news...
- Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
- Sage Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
- Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
- Sage Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA) for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022 with Rolling Submission Expected to Start in Early 2022
- Sage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
- Sage Therapeutics Launches SageCitizen Social Impact Initiative
- Sage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
- Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
- Sage Therapeutics to Present at Upcoming August Investor Conferences
- Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
- Sage Therapeutics to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
- Sage Therapeutics to Participate in SVB Leerink’s 3rd Annual CNS Forum
- Sage Therapeutics to Host Conference Call
- Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
- Sage Therapeutics Joins MTV Entertainment Group and More Than 1,300 Leading Organizations to Participate in Inaugural Mental Health Action Day
- Sage Therapeutics to Host Sage Science Spotlight: SAGE-718 In Depth
- Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Present at Upcoming May Investor Conferences
- Sage Therapeutics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021
- Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
- Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day
- Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD
- Sage Therapeutics Announces Departure of Chief Operating Officer
- Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics to Present at Upcoming Investor Conferences
- Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
- Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference
- Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
